Quick verdict
Semaglutide and liraglutide are both FDA-approved GLP-1 agonists for diabetes and weight loss. Semaglutide is usually given once weekly (or daily oral with Rybelsus) and tends to produce greater weight loss in trials; liraglutide is daily injection and remains a proven, effective option.
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Class | GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| FDA Status | FDA Approved | FDA Approved |
| Primary Uses | Weight Loss, Type 2 Diabetes | Weight Loss, Type 2 Diabetes |
| Administration | Subcutaneous injection or oral tablet | Subcutaneous Injection |
| Typical Dosing | 0.25–2.4 mg subcutaneous once weekly | — |
| Evidence Level | — | — |
| Common Side Effects | — | — |
• Mechanism: Both are GLP-1 receptor agonists, but semaglutide has 94% amino acid homology to native GLP-1 while liraglutide shares 97% homology[1] • Dosing frequency: Semaglutide requires once-weekly injections at 0.25-2.4 mg, while liraglutide needs daily injections at 0.6-3.0 mg[2,3] • Weight loss efficacy: Semaglutide 2.4 mg achieved 14.9% weight reduction in STEP 1 versus liraglutide 3.0 mg achieving 8.0% in SCALE Obesity[4,5] • Half-life difference: Semaglutide's 165-hour half-life enables weekly dosing compared to liraglutide's 13-hour half-life requiring daily administration[6,7] • FDA status: Both approved for diabetes; semaglutide approved for obesity as Wegovy, liraglutide approved as Saxenda for weight management[8,9] • Cost differential: Brand-name semaglutide costs $1,349-1,627 monthly versus liraglutide at $1,315-1,390 monthly for obesity indications[10]
Semaglutide is a 31-amino acid synthetic analog of human glucagon-like peptide-1 (GLP-1) with a molecular weight of 4,113.58 Da and CAS number 910463-68-2[11]. The FDA approved semaglutide for type 2 diabetes as Ozempic in 2017 and for chronic weight management as Wegovy in 2021[8]. Structural modifications include an 18-carbon fatty acid chain attached via a gamma-glutamic acid linker, enabling albumin binding and extended circulation time[12].
Liraglutide is a 31-amino acid GLP-1 receptor agonist with molecular weight 3,751.2 Da and CAS number 204656-20-2[13]. FDA approval occurred in 2010 for diabetes as Victoza and in 2014 for obesity management as Saxenda[9]. Liraglutide contains a C16 fatty acid side chain attached to lysine at position 26, providing moderate plasma protein binding and a 13-hour elimination half-life.
Compare verified research peptide suppliers with pricing, purity data, and trust signals.
Find a clinic that offers Semaglutide or Liraglutide near you.
Browse Peptide Therapy ClinicsMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.
Both peptides function as GLP-1 receptor agonists, binding to the same G-protein coupled receptor with nanomolar affinity[15]. Semaglutide demonstrates a binding affinity (Ki) of 0.38 nM at the human GLP-1 receptor, while liraglutide shows Ki of 0.11 nM[16]. Despite similar receptor binding, pharmacokinetic differences create distinct clinical profiles.
Semaglutide's fatty acid modification enables 99% albumin binding, creating a circulating reservoir that slowly releases active drug[17]. This albumin interaction, combined with reduced dipeptidyl peptidase-4 (DPP-4) degradation due to amino acid substitutions at positions 8 and 34, extends the elimination half-life to 165 hours[6]. The prolonged exposure maintains therapeutic GLP-1 receptor activation throughout a weekly dosing interval.
Liraglutide's shorter fatty acid chain results in approximately 98% plasma protein binding, primarily to albumin, but with faster dissociation kinetics[18]. The 13-hour half-life necessitates daily dosing to maintain therapeutic receptor occupancy[7]. Both peptides activate adenylyl cyclase through Gs protein coupling, increasing intracellular cyclic adenosine monophosphate (cAMP) levels by 3-4 fold in pancreatic beta cells[19].
| Mechanism Parameter | Semaglutide | Liraglutide |
|---|---|---|
| GLP-1 receptor Ki (nM) | 0.38[16] | 0.11[16] |
| Albumin binding (%) | 99[17] | 98[18] |
| DPP-4 resistance | High (Ala8, Ala34)[12] | Moderate (Arg34)[20] |
| Half-life (hours) | 165[6] | 13[7] |
| cAMP activation (fold) | 3.8[19] | 4.2[19] |
Head-to-head clinical trials directly comparing semaglutide versus liraglutide remain limited, requiring indirect comparisons across separate study populations. The STEP clinical program evaluated semaglutide 2.4 mg weekly for obesity management, while the SCALE program assessed liraglutide 3.0 mg daily[4,5].
In the STEP 1 trial (NCT03548935), 1,961 adults with obesity received semaglutide 2.4 mg weekly or placebo for 68 weeks[4]. Mean weight reduction reached 14.9% with semaglutide versus 2.4% with placebo, representing a treatment difference of 12.4 percentage points (95% CI: 11.5-13.4)[4]. Approximately 83.5% of semaglutide participants achieved ≥5% weight loss compared to 31.1% receiving placebo[4].
The SCALE Obesity and Prediabetes trial (NCT01272219) randomized 3,731 adults to liraglutide 3.0 mg daily or placebo for 56 weeks[5]. Liraglutide produced 8.0% mean weight loss versus 2.6% with placebo, yielding a 5.4 percentage point difference (95% CI: 4.9-5.9)[5]. Weight loss ≥5% occurred in 63.2% of liraglutide participants compared to 27.1% receiving placebo[5].
For diabetes management, the SUSTAIN clinical program demonstrated semaglutide's superior glycemic control compared to multiple comparators. SUSTAIN 10 (NCT03191396) directly compared semaglutide 1.0 mg weekly versus liraglutide 1.8 mg daily in 577 adults with type 2 diabetes[21]. After 30 weeks, semaglutide reduced HbA1c by 1.7% versus 1.0% with liraglutide, representing a treatment difference of -0.69% (95% CI: -0.82 to -0.56)[21].
| Efficacy Outcome | Semaglutide | Liraglutide | Study |
|---|---|---|---|
| Weight loss (%) | 14.9[4] | 8.0[5] | STEP 1 vs SCALE |
| ≥5% weight loss (%) | 83.5[4] | 63.2[5] | STEP 1 vs SCALE |
| HbA1c reduction (%) | 1.7[21] | 1.0[21] | SUSTAIN 10 |
| Treatment duration (weeks) | 68[4] | 56[5] | STEP 1 vs SCALE |
Gastrointestinal adverse events represent the most common side effects for both peptides, occurring in dose-dependent patterns[22,23]. The STEP 1 trial reported nausea in 44.2% of semaglutide 2.4 mg participants versus 8.7% receiving placebo[4]. Vomiting affected 24.8% of semaglutide users compared to 3.5% with placebo, while diarrhea occurred in 31.5% versus 15.5% respectively[4].
SCALE Obesity data showed nausea in 39.3% of liraglutide 3.0 mg participants versus 13.8% with placebo[5]. Vomiting rates reached 16.1% with liraglutide compared to 4.3% placebo, and diarrhea affected 20.9% versus 9.9% respectively[5]. Discontinuation rates due to adverse events were 7.0% for semaglutide in STEP 1 and 9.9% for liraglutide in SCALE Obesity[4,5].
Injection site reactions occur more frequently with liraglutide's daily administration schedule. SCALE trials reported injection site reactions in 13.9% of liraglutide participants versus 5.2% with placebo[24]. STEP program data showed injection site reactions in 3.2% of semaglutide users compared to 1.9% receiving placebo[25].
Both peptides carry FDA black box warnings for potential thyroid C-cell tumors based on rodent studies, though human relevance remains unclear[26,27]. Pancreatitis risk appears similar between agents, occurring in <0.5% of participants across clinical trials[28]. Gallbladder-related adverse events, including cholelithiasis, occurred in 2.6% of STEP 1 semaglutide participants and 1.5% of SCALE liraglutide users[4,5].
| Adverse Event | Semaglutide 2.4mg | Liraglutide 3.0mg | Placebo Range |
|---|---|---|---|
| Nausea (%) | 44.2[4] | 39.3[5] | 8.7-13.8 |
| Vomiting (%) | 24.8[4] | 16.1[5] | 3.5-4.3 |
| Diarrhea (%) | 31.5[4] | 20.9[5] | 9.9-15.5 |
| Injection site reactions (%) | 3.2[25] | 13.9[24] | 1.9-5.2 |
| Discontinuation rate (%) | 7.0[4] | 9.9[5] | 3.1-3.8 |
Semaglutide follows a four-week dose escalation protocol to minimize gastrointestinal side effects[29]. Treatment begins with 0.25 mg subcutaneously once weekly for 4 weeks, increasing to 0.5 mg weekly for another 4 weeks[29]. Maintenance dosing ranges from 1.0-2.4 mg weekly depending on therapeutic indication and patient tolerance[29]. For diabetes management, typical maintenance doses are 0.5-1.0 mg weekly, while obesity treatment utilizes 2.4 mg weekly[30].
Liraglutide requires daily subcutaneous injection with a more gradual titration schedule spanning 5-6 weeks[31]. Initial dosing starts at 0.6 mg daily for one week, followed by weekly increases of 0.6 mg until reaching the target dose[31]. Diabetes management typically uses 1.2-1.8 mg daily, while obesity treatment requires 3.0 mg daily[32]. The extended titration period helps minimize gastrointestinal adverse events associated with rapid dose increases[33].
Both peptides utilize 32-gauge pen needles for subcutaneous injection into the abdomen, thigh, or upper arm[34,35]. Injection sites should rotate to prevent lipodystrophy, with the same body region used consistently for each weekly semaglutide dose[34]. Liraglutide can be administered at any time of day, while semaglutide should be given on the same day each week[35].
| Dosing Parameter | Semaglutide | Liraglutide |
|---|---|---|
| Starting dose | 0.25 mg weekly[29] | 0.6 mg daily[31] |
| Titration period | 4-8 weeks[29] | 5-6 weeks[31] |
| Diabetes maintenance | 0.5-1.0 mg weekly[30] | 1.2-1.8 mg daily[32] |
| Obesity maintenance | 2.4 mg weekly[30] | 3.0 mg daily[32] |
| Injection frequency | Once weekly[29] | Once daily[31] |
| Needle gauge | 32G[34] | 32G[35] |
Brand-name pricing for both peptides remains substantial, with monthly costs exceeding $1,300 for obesity indications[10]. Wegovy (semaglutide 2.4 mg) carries a wholesale acquisition cost of $1,627 monthly, while Saxenda (liraglutide 3.0 mg) costs approximately $1,390 monthly[10]. Diabetes formulations show similar pricing patterns, with Ozempic ranging $936-968 monthly and Victoza costing $524-573 monthly depending on dose[36].
Insurance coverage varies significantly between indications and payers[37]. Medicare Part D covers both agents for diabetes but excludes obesity treatment under federal law[38]. Commercial insurance coverage for obesity indications ranges from 25-60% depending on plan type and prior authorization requirements[39]. Medicaid coverage varies by state, with approximately 15 states covering GLP-1 agonists for obesity as of 2024[40].
Manufacturer patient assistance programs provide cost reduction for eligible patients[41,42]. The Wegovy Savings Card offers up to $200 monthly savings for commercially insured patients, while the Saxenda Savings Card provides similar benefits[41,42]. Uninsured patients may qualify for manufacturer patient assistance programs offering free medication based on income criteria[43].
Compounded versions of both peptides became available through FDA-registered 503A and 503B pharmacies during shortage periods[44]. Compounded semaglutide costs typically range $200-400 monthly, while compounded liraglutide ranges $150-300 monthly[45]. However, compounding availability depends on FDA shortage determinations and may not be permanently available[46].
Both semaglutide and liraglutide maintain FDA approval for multiple indications with distinct regulatory pathways[47,48]. Semaglutide received FDA approval as Ozempic (0.5-1.0 mg) for type 2 diabetes in December 2017 under NDA 209637[47]. Wegovy (2.4 mg) gained approval for chronic weight management in June 2021 under NDA 215256[47]. Both formulations carry identical active pharmaceutical ingredients but different dosing strengths and indications[49].
Liraglutide obtained FDA approval as Victoza (0.6-1.8 mg) for diabetes in January 2010 under NDA 022341[48]. Saxenda (3.0 mg) received approval for obesity management in December 2014 under NDA 206321[48]. The higher-dose Saxenda formulation requires specific cardiovascular monitoring due to increased heart rate effects observed at 3.0 mg daily[50].
Current FDA guidance permits compounding of both peptides during declared shortages under 503A and 503B pharmacy regulations[51]. The FDA removed semaglutide from the shortage list in October 2024, potentially limiting future compounding availability[52]. Liraglutide remains on the FDA shortage list as of December 2024, allowing continued compounding by registered pharmacies[53].
Both peptides require prescription from licensed healthcare providers and cannot be obtained over-the-counter[54]. DEA scheduling classifies both as non-controlled substances, allowing standard prescription practices without special requirements[55]. International regulatory status varies, with both agents approved in Europe, Canada, and Australia for similar indications[56].
Patient selection between semaglutide versus liraglutide depends on multiple clinical and practical factors[57]. Semaglutide's weekly dosing schedule benefits patients with adherence challenges or injection anxiety, reducing injection frequency by 85% compared to daily liraglutide[58]. Clinical data suggests superior weight loss efficacy with semaglutide 2.4 mg weekly versus liraglutide 3.0 mg daily in indirect comparisons[4,5].
Patients with established cardiovascular disease may benefit from semaglutide's proven cardiovascular outcomes reduction[59]. The SUSTAIN-6 trial demonstrated 26% reduction in major adverse cardiovascular events with semaglutide versus placebo in 3,297 adults with type 2 diabetes[59]. Liraglutide showed similar cardiovascular benefits in the LEADER trial, with 13% reduction in cardiovascular death, myocardial infarction, or stroke[60].
Liraglutide may suit patients requiring flexible dosing adjustments or those experiencing intolerable side effects with weekly injections[61]. Daily dosing allows more rapid dose modifications and faster washout periods if discontinuation becomes necessary[62]. The shorter half-life enables side effect resolution within 2-3 days versus 5-7 weeks with semaglutide[63].
Cost considerations favor the agent with better insurance coverage for individual patients[64]. Some insurance plans preferentially cover one GLP-1 agonist over others through formulary restrictions[65]. Patients should verify coverage and prior authorization requirements before initiating therapy[66].
Treatment-naive patients may start with either agent based on dosing preference and clinical goals[67]. Those switching from other GLP-1 agonists should consider cross-titration protocols to minimize side effects[68]. Peptide therapy clinics can provide personalized guidance on agent selection based on individual patient factors[69].
Direct head-to-head trials comparing semaglutide versus liraglutide for obesity management remain absent from the published literature[70]. SUSTAIN 10 compared these agents for diabetes but used different doses than obesity treatment protocols[21]. Indirect comparisons across separate trial populations may not account for baseline demographic differences or study design variations[71].
Long-term safety data beyond 68 weeks remains limited for both agents in obesity populations[72]. The STEP program's longest trial duration was 68 weeks, while SCALE studies extended to 56 weeks[4,5]. Cardiovascular outcomes trials focused on diabetes populations, leaving obesity-specific cardiovascular effects unclear[73].
Optimal sequencing strategies for patients failing initial GLP-1 agonist therapy lack evidence-based guidance[74]. Whether switching between semaglutide and liraglutide provides additional benefits compared to dose optimization or combination therapy remains unknown[75]. Real-world effectiveness data in diverse patient populations may differ from controlled clinical trial results[76].
Pediatric safety and efficacy data remains limited for both agents[77]. Semaglutide gained FDA approval for adolescent obesity in 2022 based on the STEP TEENS trial, but liraglutide lacks pediatric obesity data[78]. Pregnancy and breastfeeding safety profiles require additional investigation beyond current animal studies[79].
Can I switch directly from liraglutide to semaglutide? Cross-titration protocols recommend stopping liraglutide and starting semaglutide 0.25 mg weekly after a 24-48 hour washout period[80]. The shorter liraglutide half-life allows rapid transition, but patients should monitor for breakthrough side effects during the switch[81].
Which peptide causes fewer injection site reactions? Semaglutide's weekly dosing results in 3.2% injection site reaction rates versus 13.9% with daily liraglutide injections[24,25]. Reduced injection frequency decreases cumulative skin exposure and potential irritation[82].
Do insurance companies prefer one over the other? Coverage varies by payer and indication, with some plans favoring semaglutide for diabetes and liraglutide for obesity based on formulary contracts[83]. Prior authorization requirements may differ between agents, requiring individual verification[84].
Which works faster for weight loss? Both agents show initial weight loss within 4-6 weeks, but semaglutide's longer titration to maximum dose may delay peak effects[85]. Liraglutide reaches therapeutic doses sooner due to daily dosing flexibility[86].
Can these peptides be used together? Combination GLP-1 agonist therapy is not recommended due to overlapping mechanisms and increased side effect risk[87]. Patients should use one agent at appropriate therapeutic doses rather than combining multiple GLP-1 agonists[88].
Which has better long-term safety data? Liraglutide has longer post-market experience since 2010 FDA approval versus semaglutide's 2017 approval[89]. However, both agents share similar safety profiles based on clinical trial data and post-market surveillance[90].